Dyadic International (DYAI) Net Income towards Common Stockholders (QoQ) (2018 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Income towards Common Stockholders (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -25.62% |
| Dec 31, 2025 | 21.95% |
| Sep 30, 2025 | -10.08% |
| Jun 30, 2025 | 11.67% |
| Mar 31, 2025 | -32.20% |
| Dec 31, 2024 | -823.34% |
| Sep 30, 2024 | 91.76% |
| Jun 30, 2024 | 3.25% |
| Mar 31, 2024 | 0.58% |
| Dec 31, 2023 | -28.34% |
| Sep 30, 2023 | 25.99% |
| Jun 30, 2023 | -12.10% |
| Mar 31, 2023 | 9.35% |
| Dec 31, 2022 | -18.64% |
| Sep 30, 2022 | 44.98% |
| Jun 30, 2022 | -19.93% |
| Mar 31, 2022 | 34.94% |
| Dec 31, 2021 | -26.89% |
| Sep 30, 2021 | 13.66% |
| Jun 30, 2021 | 99.88% |